Fig. 6

Pathological and radiographic outcomes of nivolumab alone or in combination with ipilumumab or chemotherapy in early-stage and metastatic NSCLC. The pathologic complete response (pCR, solid bar in orange) and major pathologic response (MPR, solid bar in blue) rate (%) by histopathological evaluation were shown in resectable, early-stage NSCLC. No pathological stage is available for patients with unresectable NSCLC. The overall response rate (ORR) is the radiographic evaluation of tumor response by RECIST, which is higher in early-stage NSCLC compared to mNSCLC. Per RECIST V1.1, CR (dashed bar in orange) is defined as disappearance of all targeted lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response (PR, dashed bar in blue) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. This PR criteria correlate with at least a 50% decrease in tumor volume